JFL Life Sciences (NSE:JFLLIFE) Total Equity: ₹394.6 Mil (As of Mar. 2025)


NSE:JFLLIFE JFL Life Sciences Ltd NSE:JFLLIFE
70 GF Score
Price ₹10.45
GF Value ₹35.77
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is JFL Life Sciences Total Equity?

JFL Life Sciences NSE:JFLLIFE -4.57% 70 Total Equity is ₹394.6 Mil as of Mar. 2025. GuruFocus rates NSE:JFLLIFE with a GF Score™ of 70/100 and a GF Value™ of ₹35.77 (Significantly Undervalued). The stock has 2 warning signs investors should review.

JFL Life Sciences's total equity for the quarter that ended in Mar. 2025 was ₹394.6 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

JFL Life Sciences Total Equity Historical Data

* Premium members only.

The historical data trend for JFL Life Sciences's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JFL Life Sciences Total Equity Chart

JFL Life Sciences Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Total Equity
Get a 7-Day Free Trial 68.73 112.90 322.68 355.75 394.55

JFL Life Sciences Semi-Annual Data
Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Total Equity Get a 7-Day Free Trial 68.73 112.90 322.68 355.75 394.55
NSE:JFLLIFE
70GF Score
JFL Life Sciences Ltd NSE:JFLLIFE
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

JFL Life Sciences Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

JFL Life Sciences's Total Equity for the fiscal year that ended in Mar. 2025 is calculated as

Total Equity=Total Assets(Q: Mar. 2025 )-Total Liabilities(Q: Mar. 2025 )
=719.14-324.586
=394.6

JFL Life Sciences's Total Equity for the quarter that ended in Mar. 2025 is calculated as

Total Equity=Total Assets(Q: Mar. 2025 )-Total Liabilities(Q: Mar. 2025 )
=719.14-324.586
=394.6

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of ₹394.6 Mil mean?
JFL Life Sciences (NSE:JFLLIFE) has a Total Equity of ₹394.6 Mil as of Mar. 2025. The total amount of equity as record on a company's balance sheet. View historical data for JFL Life Sciences and its competitors.
Is JFL Life Sciences' Total Equity too high?
JFL Life Sciences' current Total Equity is ₹394.6 Mil. Overall, JFL Life Sciences has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JFL Life Sciences' Total Equity compare to ZTS and UTHR?
JFL Life Sciences' Total Equity of ₹394.6 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for JFL Life Sciences and its competitors. JFL Life Sciences's current Total Equity is ₹394.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JFL Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, JFL Life Sciences (NSE:JFLLIFE) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹35.77, compared to a current price of ₹10.45 — trading 70.8% below its estimated fair value. The current Total Equity is ₹394.6 Mil. JFL Life Sciences' overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For JFL Life Sciences (NSE:JFLLIFE), the current Total Equity is ₹394.6 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is JFL Life Sciences (NSE:JFLLIFE) Overvalued in 2026?

Based on GuruFocus' analysis, JFL Life Sciences stock appears to be undervalued. The current stock price of ₹10.45 is trading 70.8% below its estimated GF Value™ of ₹35.77. GuruFocus considers JFL Life Sciences to be Significantly Undervalued.

Key valuation signals for NSE:JFLLIFE:

  • Total Equity: ₹394.6 Mil
  • GF Value™: ₹35.77 vs. price of ₹10.45 (70.8% below fair value)
  • GF Score™: 70/100 with 2 warning signs

No single metric tells the full story. See the NSE:JFLLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

JFL Life Sciences Business Description

Address Jodhpur Cross Road, 309, Satyam Mall, Opposite Saman Complex, Near Vishweshwar Mahadev Mandir, Settelite, Ahmedabad, GJ, IND, 380015
JFL Life Sciences Ltd is engaged in the business of manufacturing pharmaceutical products. The company's product portfolio consists of Dry powder injections (B-Lactam), Tablets and Capsules (B-Lactam) solid oral dosage forms, and general tablets and capsules. Its operating segment comprises of manufacturing and selling of pharmaceutical products. Geographically, the company sells its products both in India and outside India.
70GF Score

Get the complete analysis for NSE:JFLLIFE

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹10.45
Price
₹35.77
GF Value